MBRX RSI Chart
Last 7 days
6.3%
Last 30 days
18.2%
Last 90 days
912.0%
Trailing 12 Months
690.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 26, 2023 | george robert e. | bought | 10,000 | 0.69 | 14,493 | - |
Dec 26, 2023 | foster jonathan p. | bought | 20,000 | 0.69 | 28,986 | chief financial officer |
Dec 26, 2023 | klemp walter v | bought | 129,999 | 0.69 | 188,404 | ceo and president |
Jul 11, 2023 | klemp walter v | sold (taxes) | -1,898 | 0.5903 | -3,216 | ceo and president |
Jul 11, 2023 | klemp walter v | acquired | - | - | 13,204 | ceo and president |
Jul 02, 2023 | klemp walter v | sold (taxes) | -2,074 | 0.5788 | -3,584 | ceo and president |
Jul 02, 2023 | klemp walter v | acquired | - | - | 14,717 | ceo and president |
Jun 20, 2023 | foster jonathan p. | acquired | - | - | 40,667 | chief financial officer |
Jun 20, 2023 | klemp walter v | acquired | - | - | 56,250 | ceo and president |
Jun 20, 2023 | klemp walter v | sold (taxes) | -7,807 | 0.57 | -13,697 | ceo and president |
Which funds bought or sold MBRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | sold off | -100 | -61,287 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -55,497 | - | -% |
May 15, 2024 | Royal Bank of Canada | new | - | - | - | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | -17,000 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 3,670 | 3,670 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -6,178 | - | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | new | - | 877,605 | 877,605 | 0.01% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 41.00 | 41.00 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -118 | - | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 2,500 | 2,500 | -% |
Unveiling Moleculin Biotech Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Moleculin Biotech Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Moleculin Biotech Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -19.3% | 30,845 | 38,217 | 39,523 | 47,115 | 51,062 | 57,422 | 65,372 | 73,255 | 78,801 | 84,090 | 88,702 | 93,534 | 99,784 | 29,031 | 27,144 | 31,380 | 25,472 | 25,235 | 30,398 | 31,854 | 21,298 |
Current Assets | -27.8% | 18,957 | 26,273 | 27,603 | 35,380 | 39,289 | 45,596 | 53,493 | 61,322 | 67,260 | 72,497 | 77,070 | 81,836 | 88,019 | 17,198 | 15,250 | 19,749 | 13,787 | 13,484 | 18,586 | 20,202 | 9,613 |
Cash Equivalents | -28.6% | 16,824 | 23,550 | 24,579 | 32,172 | 37,300 | 43,145 | 50,392 | 57,999 | 66,104 | 70,903 | 75,178 | 79,506 | 86,293 | 15,173 | 12,795 | 16,734 | 11,649 | 10,735 | 15,409 | 18,695 | 8,782 |
Net PPE | -11.8% | 240 | 272 | 225 | 229 | 244 | 275 | 306 | 339 | 312 | 338 | 353 | 395 | 438 | 483 | 522 | 238 | 271 | 316 | 358 | 401 | 431 |
Liabilities | -23.8% | 9,258 | 12,144 | 4,385 | 6,847 | 5,378 | 5,231 | 6,955 | 6,896 | 6,136 | 5,097 | 7,443 | 8,834 | 11,268 | 11,271 | 12,677 | 15,751 | 10,180 | 9,664 | 11,423 | 9,762 | 6,616 |
Current Liabilities | -20.6% | 5,408 | 6,815 | 3,888 | 6,554 | 5,032 | 4,819 | 6,362 | 5,859 | 4,834 | 3,622 | 3,656 | 3,350 | 4,578 | 2,920 | 3,438 | 3,739 | 3,235 | 3,570 | 11,119 | 9,591 | 6,436 |
Shareholder's Equity | -17.2% | 21,587 | 26,073 | 35,138 | 40,268 | 45,684 | 52,191 | 58,417 | 66,359 | 72,665 | 78,993 | 81,259 | 84,700 | 88,516 | 17,760 | 14,467 | 15,629 | 15,292 | 15,571 | 18,975 | 22,092 | 14,682 |
Retained Earnings | -3.8% | -136,574 | -131,604 | -121,300 | -115,726 | -109,750 | -101,835 | -95,065 | -86,454 | -79,677 | -72,810 | -69,984 | -65,605 | -61,361 | -56,916 | -54,277 | -50,900 | -40,800 | -39,561 | -35,763 | -31,600 | -30,400 |
Additional Paid-In Capital | 0.3% | 158,177 | 157,653 | 156,446 | 155,957 | 155,396 | 153,985 | 153,450 | 152,762 | 152,260 | 151,733 | 151,175 | 150,231 | 149,788 | 74,671 | 68,649 | 66,428 | 56,011 | 55,055 | 54,673 | 53,643 | 45,021 |
Accumulated Depreciation | -100.0% | - | 896 | - | - | - | 769 | - | - | - | 638 | - | - | - | 474 | - | - | - | 284 | - | - | - |
Shares Outstanding | - | 2,312 | - | 1,987 | 1,986 | 1,973 | - | 1,906 | 1,906 | 1,905 | 1,905 | 1,754 | 1,897 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 16,000 | - | - | - | 40,000 | - | - | - | 101,000 | - | - | - | 52,000 | - | - | - | 48,000 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -24.2% | -6,717 | -5,407 | -7,551 | -5,126 | -6,017 | -7,256 | -7,577 | -8,001 | -4,805 | -4,300 | -4,295 | -6,805 | -3,600 | -3,124 | -5,347 | -5,000 | -4,300 | -4,677 | -3,327 | -5,347 | -3,847 |
Share Based Compensation | 2.9% | 493 | 479 | 493 | 513 | 499 | 535 | 699 | 514 | 527 | 556 | 979 | 433 | 405 | 415 | 460 | 408 | 397 | 382 | 489 | 318 | 348 |
Cashflow From Investing | 100.0% | - | -81.00 | -28.00 | -15.00 | - | - | - | -61.00 | -6.00 | -19.00 | - | - | - | -14.00 | -340 | -18.00 | -2.00 | -9.00 | -8.00 | -19.00 | -15.00 |
Cashflow From Financing | -100.0% | - | 4,465 | -4.00 | 49.00 | 141 | - | -11.00 | -12.00 | - | - | -24.00 | - | 74,748 | 5,484 | 1,762 | 10,012 | 5,291 | - | 52.00 | 15,281 | 5,521 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues | $ 0 | $ 0 |
Operating expenses: | ||
Research and development | 4,252 | 5,687 |
General and administrative | 2,393 | 2,637 |
Depreciation and amortization | 32 | 30 |
Total operating expenses | 6,677 | 8,354 |
Loss from operations | (6,677) | (8,354) |
Other income: | ||
Gain from change in fair value of warrant liability | 1,455 | 39 |
Other income, net | 11 | 8 |
Interest income, net | 241 | 392 |
Net loss | $ (4,970) | $ (7,915) |
Net loss per common share - basic and diluted (in dollars per share) | $ (2.02) | $ (4.13) |
Weighted average common shares outstanding, basic and diluted (in shares) | 2,466,174 | 1,916,665 |
Net loss | $ (4,970) | $ (7,915) |
Other comprehensive loss: | ||
Foreign currency translation | (9) | (4) |
Comprehensive loss | $ (4,979) | $ (7,919) |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 16,824 | $ 23,550 |
Prepaid expenses and other current assets | 2,133 | 2,723 |
Total current assets | 18,957 | 26,273 |
Furniture and equipment, net | 240 | 272 |
Intangible assets | 11,148 | 11,148 |
Operating lease right-of-use asset | 500 | 524 |
Total assets | 30,845 | 38,217 |
Liabilities, Current [Abstract] | ||
Accounts payable | 2,104 | 2,498 |
Accrued expenses and other current liabilities | 3,304 | 4,317 |
Total current liabilities | 5,408 | 6,815 |
Operating lease liability - long-term, net of current portion | 450 | 474 |
Warrant liability - long-term | 3,400 | 4,855 |
Total liabilities | 9,258 | 12,144 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,311,536 and 2,227,516 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2 | 33 |
Additional paid-in capital | 158,177 | 157,653 |
Accumulated other comprehensive income (loss) | (18) | (9) |
Accumulated deficit | (136,574) | (131,604) |
Total stockholders’ equity | 21,587 | 26,073 |
Total liabilities and stockholders’ equity | $ 30,845 | $ 38,217 |